Definitive Contract HHSN272201600020C

This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...

This is a $18,005,775.00 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Vaxine PTY LTD, a for-profit organization based in Australia. The contract is for the advanced development of the H7-Advax pandemic vaccine candidate through Phase 1 clinical trials, including the delivery of preliminary data regarding the adjuvant formulations and the manufactured product. The contract does not have a set-aside designation,...

This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI...

This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...

This is a $30,320,960.00 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the establishment of mRNA vaccine capability in support of NIAID's Vaccine Research Center (VRC) programs. The contract is a cost-plus-fixed-fee type with a period of performance through June 17, 2030. There is no set-aside...

This federal contract award, HHSN272201600011C, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the University of Massachusetts Medical School (UMMS) for "STAGED VACCINE DEVELOPMENT". The $17,298,573.00 cost-no-fee contract does not have a set-aside designation. Under this contract, UMMS serves as the prime contractor and has subcontracted a portion of the work to the University...

This is a $20,264.00 fixed-price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization. The award is for process development work related to vaccine candidates, including those for SARS-CoV-2. This award appears to be part of a larger indefinite delivery/indefinite quantity (IDIQ) contract vehicle that IAVI holds with NIAID for preclinical services supporting...

This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Sanofi Pasteur Biologics, LLC, a foreign-owned for-profit organization. The contract is for the development and testing of a modified vaccinia Ankara (MVA) vaccine, with a ceiling value of $12,667,339.96. The contract is a definitive, cost-plus-fixed-fee contract type, with a final completion date of January 8, 2007. The...

This is a definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AlphaVax Human Vaccines Inc. for R&D in physical science and exploratory development. The contract has a ceiling value of $16,660,130.44 and an ultimate completion date of August 14, 2012. It was initially awarded on September 26, 2003 and does not have a set-aside designation. AlphaVax Human Vaccines Inc. is a for-profit organization that...

This is a $1,327,640.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization. The contract is for "COORDINATION AND TECHNICAL SUPPORT" under NIAID's program for "PROCESS AND ANALYTICAL SUPPORT FOR DEVELOPMENT OF HIV VACCINES". IAVI, as the prime contractor, will provide a...